MRD-guided therapy for CLL balances treatment cessation risks with cumulative toxicity concerns, offering a promising alternative to continuous or fixed-duration therapies. The VISION/HOVON141 trial ...
Imbruvica plus venetoclax significantly extends PFS in untreated CLL patients compared to chlorambucil plus Gazyva, with 52 months versus 31 months. The combination therapy shows durable efficacy and ...
MRD-guided retreatment with anti-CD20 antibodies may improve survival outcomes in high-risk, relapsed CLL patients by initiating therapy before clinical relapse. The study showed MRD-triggered ...
Researchers review available clinical evidence for retreatment with venetoclax, alone or in combination, in patients with relapsed chronic lymphocytic leukemia.
Suchitra Sundaram, MD, describes the excitement around the American Society of Hematology (ASH) 2024 meeting in the chronic lymphocytic leukemia (CLL) community, with promising updates on innovative ...
SAN DIEGO -- Single-agent epcoritamab (Epkinly) achieved encouraging response rates in patients with heavily-pretreated chronic lymphocytic leukemia (CLL), according to early results from a phase I ...
MRD quantification allows for improved PFS prediction in both patients who achive PR and CR, which thus supports its application in all responders. In contrast to residual lymphadenopathy, persisting ...
Developments in chronic lymphocytic leukemia (CLL) this year included the first CAR T-cell therapy approval for the chronic blood cancer, potential treatments for Richter transformation, and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results